User login
Key clinical point: Baricitinib monotherapy improved clinically burdensome symptom of skin pain on the first day itself after the first dose in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: By day 2, skin pain numerical rating scale scores changed significantly from baseline with baricitinib vs placebo in BREEZE-AD1 (baricitinib 4 mg, −11.9%; 2 mg, −6.4%; 1 mg, −6.2%; all P less than .05), BREEZE-AD2 (baricitinib 4 mg, −12.6%; 2 mg, −5.6%; 1 mg, −6.9%; all P less than .05), and BREEZE-AD7 (baricitinib 4 mg, −6.9%; 2 mg, −7.9%; both P less than .05).
Study details: Findings are from an analysis of 3 phase 3 trials (BREEZE-AD1, BREEZE-AD2, and BREEZE-AD7) including 1,568 patients with moderate-to-severe AD with inadequate response to existing topical therapies who were randomly assigned to baricitinib or placebo with or without topical corticosteroids.
Disclosures: This work was funded by Eli Lilly and Company. Some of the authors declared receiving grants, honoraria, consulting, and/or lecturing fees from and/or serving as advisory board member, speaker, and/or investigator for various sources including Eli Lilly. Two authors declared being employees and shareholders of Eli Lilly.
Source: Thyssen JP et al. Dermatol Ther (Heidelb). 2021 Jul 18. doi: 10.1007/s13555-021-00577-x.
Key clinical point: Baricitinib monotherapy improved clinically burdensome symptom of skin pain on the first day itself after the first dose in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: By day 2, skin pain numerical rating scale scores changed significantly from baseline with baricitinib vs placebo in BREEZE-AD1 (baricitinib 4 mg, −11.9%; 2 mg, −6.4%; 1 mg, −6.2%; all P less than .05), BREEZE-AD2 (baricitinib 4 mg, −12.6%; 2 mg, −5.6%; 1 mg, −6.9%; all P less than .05), and BREEZE-AD7 (baricitinib 4 mg, −6.9%; 2 mg, −7.9%; both P less than .05).
Study details: Findings are from an analysis of 3 phase 3 trials (BREEZE-AD1, BREEZE-AD2, and BREEZE-AD7) including 1,568 patients with moderate-to-severe AD with inadequate response to existing topical therapies who were randomly assigned to baricitinib or placebo with or without topical corticosteroids.
Disclosures: This work was funded by Eli Lilly and Company. Some of the authors declared receiving grants, honoraria, consulting, and/or lecturing fees from and/or serving as advisory board member, speaker, and/or investigator for various sources including Eli Lilly. Two authors declared being employees and shareholders of Eli Lilly.
Source: Thyssen JP et al. Dermatol Ther (Heidelb). 2021 Jul 18. doi: 10.1007/s13555-021-00577-x.
Key clinical point: Baricitinib monotherapy improved clinically burdensome symptom of skin pain on the first day itself after the first dose in patients with moderate-to-severe atopic dermatitis (AD).
Major finding: By day 2, skin pain numerical rating scale scores changed significantly from baseline with baricitinib vs placebo in BREEZE-AD1 (baricitinib 4 mg, −11.9%; 2 mg, −6.4%; 1 mg, −6.2%; all P less than .05), BREEZE-AD2 (baricitinib 4 mg, −12.6%; 2 mg, −5.6%; 1 mg, −6.9%; all P less than .05), and BREEZE-AD7 (baricitinib 4 mg, −6.9%; 2 mg, −7.9%; both P less than .05).
Study details: Findings are from an analysis of 3 phase 3 trials (BREEZE-AD1, BREEZE-AD2, and BREEZE-AD7) including 1,568 patients with moderate-to-severe AD with inadequate response to existing topical therapies who were randomly assigned to baricitinib or placebo with or without topical corticosteroids.
Disclosures: This work was funded by Eli Lilly and Company. Some of the authors declared receiving grants, honoraria, consulting, and/or lecturing fees from and/or serving as advisory board member, speaker, and/or investigator for various sources including Eli Lilly. Two authors declared being employees and shareholders of Eli Lilly.
Source: Thyssen JP et al. Dermatol Ther (Heidelb). 2021 Jul 18. doi: 10.1007/s13555-021-00577-x.